Immunohistochemistry and c-kit gene analysis in determining malignancy in gastrointestinal stromal tumors

Hepato-Gastroenterology

Volumn 50, Issue 53, 2003, Pages 1431-1435

  Yamaguchi, Masahiko ^a,c   Tate, Genshu ^a   Endo, Yutaka ^a   Miyaki, Michiko ^b  

^a SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

^b TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^c DOKKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

GIST; Ki 67; Mutation in exon 11 of c kit gene; p53

Indexed keywords

STEM CELL FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EXON; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MITOSIS; PRIORITY JOURNAL; RECURRENT DISEASE; TUMOR NECROSIS; TUMOR VOLUME;

ADULT; AGED; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; PROTO-ONCOGENE PROTEINS C-KIT; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0141651610     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Dougherty MJ, Compton C, Talbert M, Wood WC: Sarcomas of the gastrointestinal tract. Separation into favorable and unfavorable prognostic groups by mitotic count. Ann Surg 1991; 214:569-574.
2. Seidal T, Edvardsson H: Expression of c-kit (CD117) and Ki67 provides information about the possible cell of origin and clinical course of gastrointestinal stromal tumours. Histopathology 1999; 34:416-424.
3. O'Reilly PE, Raab SS, Niemann TH, Rodgers JR, Robinson RA: p53, proliferating cell nuclear antigen, and Ki-67 expression in extrauterine leiomyosarcomas. Mod Pathol 1997; 10:91-97.
4. Sarlomo-Rikala M, Kovatich AJ, Barusevcius A, Miettinen M: CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol 1998; 11:728-734.
5. Miettinen A, Sarlomo-Rikala M, Lasota J: Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol 1999; 30:1213-1220.
6. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Tunio GM, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279:577-580.
7. Lasota J, Jasinski M, Sarlomo-Rikala M, Miettinen M: Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol 1999; 154:53-60.
8. Taniguchi M, Nishida T, Hirota S, Isozaki K, Ito T, Nomura T, Matsuda H, Kitamura Y: Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res 1999; 59:4297-4300.
9. Vandenbark GR, deCastro CM, Taylor H, Dew-Knight S, Kaufman RE: Cloning and structural analysis of the human c-kit gene. Oncogene 1992; 7:1259-1266.
10. Emory TS, Sobin LH, Lukes L, Lee DH, O'Leary TJ: Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site. Am J Surg Pathol 1999; 23:82-87.
11. Kubbutat MHG, Jones SN, Vousden SN: Regulation of p53 stability by Mdm2. Nature 1997; 387:299-303.
12. Lasota J, Wozniak A, Sarlomo-Rikala M, Rys J, Kordek R, Nassar A, Sobin LH, Miettinen M: Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 cases. Am J Pathol 2000; 157:1091-1095.
13. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ: Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000; 96:925-932.
14. H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman S, Capdeville R, Dimitrijevic S, Druker B, Demetri GD: Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344:1052-1056.
15. van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S, Martens M, Webb A, Sciot R, Van Glabbeke M, Silberman S, Nielsen OS: Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001; 358:1421-1423.